CD274 and inflammatory breast carcinoma: Moreover, PD-L1 expression is a prognosis factor for poor outcomes in soft-tissue sarcomas [29], and the frequent expression of PD-L1 in inflammatory breast cancer indicates that it has a weak response to chemotherapy [30].